Hallucinogens and Dissociative Drugs Research Report

  1. Barbosa PC, Mizumoto S, Bogenschutz MP, Strassman RJ. Health status of ayahuasca users. Drug Test Anal. 2012; 4(7-8):601-609.
  2. Barker SA, McIlhenny EH, Strassman R. A critical review of reportsof endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010. Drug Test Anal. 2012; Jul-Aug;4(7-8):617-35.
  3. Bogenschutz MP, Pommy JM. Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses. Drug Test Anal. 2012;4(7-8):543-555.
  4. Bonson KR. Hallucinogenic drugs. In: Encyclopedia of Life Sciences. United Kingdom: Nature Publishing Group; 2001.
  5. Bouso JC, González D, Fondevila S, et al. Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study. PLoS One. 2012;7(8).
  6. Cunningham CW, Rothman RB, Prisinzano TE. Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev. 2011;63(2):316-347.
  7. Gilmore HT. Peyote use during pregnancy. S D J Med. 2001;54(1):27-29.
  8. Halpern JH, Sherwood AR, Hudson JI, Yurgelun-Todd D, Pope HG Jr. Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychiatry. 2005;58(8):624-631.
  9. Hibell B, Guttormsson U, Ahlström S, et al. The 2011 ESPAD Report: Substance Use Among Students in 36 European Countries. Stockholm, Sweden: The Swedish Council for Information on Alcohol and Other Drugs (CAN); 2012.
  10. Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national results on drug use: 1975-2014. Overview of key findings on Adolescent Drug Use. Ann Arbor, MI: Institute for Social Research, The University of Michigan; 2014.
  11. Lee HM, and Roth BL. Hallucinogen actions on human brain revealed. Proc Natl Acad Sci U S A. 2012; 109(6):1820-1821.
  12. MacLean KA, Johnson MW, Reissig CJ, Prisinzano TE, Griffiths RR. Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology (Berl). 2013;226(2):381-392.
  13. McKenna, DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol Ther. 2004;102(2):111-129.
  14. Morgan CJ, Curran HV, Independent Scientific Committee on Drugs. Ketamine use: a review. Addiction. 2012;107(1):27-38.
  15. Morris BJ, Cochran SM, and Pratt JA. PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol. 2005;5(1):101-106.
  16. Nichols DE. Hallucinogens. Pharmacol Ther. 2004; 101(2):131-181.
  17. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008;14(4):295-314.
  18. Schindler EA, Dave KD, Smolock EM, Aloyo VJ, Harvey JA. Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2- aminopropane (DOI) and lysergic acid diethylamide (LSD). Pharmacol Biochem Behav. 2012;101(1): 69-76.
  19. Strassman RJ. Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res. 1996;73(1-2):121-124.
  20. Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014. HHS Publication No. (SMA) 14-4887. NSDUH Series H-49.
  21. Winstock AR, Kaar S, Borschmann R. Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample. J Psychopharmacol. 2014;28(1):49-54.